{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T13:28:26Z","timestamp":1745328506657},"reference-count":223,"publisher":"Spandidos Publications","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Oncol"],"DOI":"10.3892\/ijo.2019.4847","type":"journal-article","created":{"date-parts":[[2019,7,23]],"date-time":"2019-07-23T04:36:03Z","timestamp":1563856563000},"source":"Crossref","is-referenced-by-count":7,"title":["Current strategies against persistent human papillomavirus infection (Review)"],"prefix":"10.3892","author":[{"given":"Yu","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Gynecology and Obstetrics, Development and Related Diseases of Women and Children Key Laboratory of Sichuan Province, Key Laboratory of Birth Defects and Related Diseases of Women and Children, Ministry of Education, West China Second Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongyi","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Gynecology and Obstetrics, Development and Related Diseases of Women and Children Key Laboratory of Sichuan Province, Key Laboratory of Birth Defects and Related Diseases of Women and Children, Ministry of Education, West China Second Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruyu","family":"Pi","sequence":"additional","affiliation":[{"name":"Department of Gynecology and Obstetrics, Development and Related Diseases of Women and Children Key Laboratory of Sichuan Province, Key Laboratory of Birth Defects and Related Diseases of Women and Children, Ministry of Education, West China Second Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Gynecology and Obstetrics, Development and Related Diseases of Women and Children Key Laboratory of Sichuan Province, Key Laboratory of Birth Defects and Related Diseases of Women and Children, Ministry of Education, West China Second Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xia","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Gynecology and Obstetrics, Development and Related Diseases of Women and Children Key Laboratory of Sichuan Province, Key Laboratory of Birth Defects and Related Diseases of Women and Children, Ministry of Education, West China Second Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaorong","family":"Qi","sequence":"additional","affiliation":[{"name":"Department of Gynecology and Obstetrics, Development and Related Diseases of Women and Children Key Laboratory of Sichuan Province, Key Laboratory of Birth Defects and Related Diseases of Women and Children, Ministry of Education, West China Second Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2019,7,23]]},"reference":[{"key":"key20200713185945_b1-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1001\/jama.297.8.813","article-title":"Prevalence of HPV infection among females in the United States","volume":"297","author":"Dunne","year":"2007","journal-title":"JAMA"},{"issue":"Suppl 5","key":"key20200713185945_b2-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"F12","DOI":"10.1016\/j.vaccine.2012.07.055","article-title":"Global burden of human papil-lomavirus and related diseases","volume":"30","author":"Forman","year":"2012","journal-title":"Vaccine"},{"key":"key20200713185945_b3-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1002\/ijc.30716","article-title":"Worldwide burden of cancer attributable to HPV by site, country and HPV type","volume":"141","author":"de Martel","year":"2017","journal-title":"Int J Cancer"},{"key":"key20200713185945_b4-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"e609","DOI":"10.1016\/S2214-109X(16)30143-7","article-title":"Global burden of cancers attributable to infections in 2012: A synthetic analysis","volume":"4","author":"Plummer","year":"2016","journal-title":"Lancet Glob Health"},{"key":"key20200713185945_b5-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"E359","DOI":"10.1002\/ijc.29210","article-title":"Cancer incidence and mortality worldwide: Sources methods and major patterns in GLOBOCAN 2012","volume":"136","author":"Ferlay","year":"2015","journal-title":"Int J Cancer"},{"key":"key20200713185945_b6-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"2675","DOI":"10.1093\/annonc\/mdr015","article-title":"Worldwide burden of cervical cancer in 2008","volume":"22","author":"Arbyn","year":"2011","journal-title":"Ann Oncol"},{"key":"key20200713185945_b7-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"614","DOI":"10.3390\/jcm4040614","article-title":"Safety and efficacy data on vaccines and immunization to human papillomavirus","volume":"4","author":"Kash","year":"2015","journal-title":"J Clin Med"},{"key":"key20200713185945_b8-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrc2050","article-title":"The natural history of cervical HPV infection: Unresolved issues","volume":"7","author":"Woodman","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"key20200713185945_b9-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1097\/AOG.0b013e3182883a34","article-title":"2012 ASCCP Consensus Guidelines Conference: 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors","volume":"121","author":"Massad","year":"2013","journal-title":"Obstet Gynecol"},{"key":"key20200713185945_b10-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1086\/341782","article-title":"Incidence, prevalence, and clearance of type-specific human papillomavirus infections: The Young Women's Health Study","volume":"186","author":"Giuliano","year":"2002","journal-title":"J Infect Dis"},{"key":"key20200713185945_b11-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1002\/j.1460-2075.1984.tb01944.x","article-title":"A new type of papillomavirus DNA, its presence in genital cancer biopsies and in cell lines derived from cervical cancer","volume":"3","author":"Boshart","year":"1984","journal-title":"EMBO J"},{"key":"key20200713185945_b12-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"3812","DOI":"10.1073\/pnas.80.12.3812","article-title":"A papil-lomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions","volume":"80","author":"D\u00fcrst","year":"1983","journal-title":"Proc Natl Acad Sci USA"},{"key":"key20200713185945_b13-ijo-55-03-0570","first-page":"107","article-title":"HPV negative cervical cancers and primary HPV screening","volume":"10","author":"Tjalma","year":"2018","journal-title":"Facts Views Vis Obgyn"},{"key":"key20200713185945_b14-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1056\/NEJMoa021641","article-title":"Epidemiologic classification of human papillomavirus types associated with cervical cancer","volume":"348","author":"Mu\u00f1oz","year":"2003","journal-title":"N Engl J Med"},{"key":"key20200713185945_b15-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1016\/S1470-2045(10)70230-8","article-title":"Human papillomavirus genotype attribution in invasive cervical cancer: A retrospective cross-sectional worldwide study","volume":"11","author":"de Sanjose","year":"2010","journal-title":"Lancet Oncol"},{"key":"key20200713185945_b16-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1002\/ijc.25671","article-title":"Human papillomavirus genotype distribution in anal cancer in France: The EDiTH V study","volume":"129","author":"Abramowitz","year":"2011","journal-title":"Int J Cancer"},{"key":"key20200713185945_b17-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1002\/ijc.24116","article-title":"Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: A meta-analysis","volume":"124","author":"De Vuyst","year":"2009","journal-title":"Int J Cancer"},{"key":"key20200713185945_b18-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1186\/1471-2407-12-398","article-title":"HPV infection, anal intra-epithelial neoplasia (AIN) and anal cancer: Current issues","volume":"12","author":"Stanley","year":"2012","journal-title":"BMC Cancer"},{"key":"key20200713185945_b19-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/j.ygyno.2005.02.012","article-title":"Is the assumed natural history of vulvar intraepithelial neoplasia III based on enough evidence? A systematic review of 3322 published patients","volume":"97","author":"van Seters","year":"2005","journal-title":"Gynecol Oncol"},{"key":"key20200713185945_b20-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1001\/jama.2012.101","article-title":"Prevalence of oral HPV infection in the United States, 2009-2010","volume":"307","author":"Gillison","year":"2012","journal-title":"JAMA"},{"key":"key20200713185945_b21-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"4294","DOI":"10.1200\/JCO.2011.36.4596","article-title":"Human papillomavirus and rising oropharyngeal cancer incidence in the United States","volume":"29","author":"Chaturvedi","year":"2011","journal-title":"J Clin Oncol"},{"key":"key20200713185945_b22-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1111\/j.1442-2050.2007.00726.x","article-title":"No association of high-risk human papillomavirus with esophageal squamous cell carcinomas among Koreans, as determined by polymerase chain reaction","volume":"21","author":"Koh","year":"2008","journal-title":"Dis Esophagus"},{"key":"key20200713185945_b23-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"10143","DOI":"10.7314\/APJCP.2014.15.23.10143","article-title":"Prevalence of human papillomavirus 16 in esophageal cancer among the Chinese population: A systematic review and meta-analysis","volume":"15","author":"Zhang","year":"2014","journal-title":"Asian Pac J Cancer Prev"},{"key":"key20200713185945_b24-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1158\/1055-9965.EPI-11-1206","article-title":"Human papillomavirus infection and esophageal squamous cell carcinoma: A case-control study","volume":"21","author":"Guo","year":"2012","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"key20200713185945_b25-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/j.annepidem.2013.07.002","article-title":"Human papillomavirus types 16 and 18 in esophagus squamous cell carcinoma: A meta-analysis","volume":"23","author":"Yong","year":"2013","journal-title":"Ann Epidemiol"},{"key":"key20200713185945_b26-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"e69238","DOI":"10.1371\/journal.pone.0069238","article-title":"The aetiological role of human papillomavirus in oesophageal squamous cell carcinoma: A meta-analysis","volume":"8","author":"Liyanage","year":"2013","journal-title":"PLoS One"},{"key":"key20200713185945_b27-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1093\/jnci\/djr499","article-title":"InterSCOPE study: Associations between esophageal squamous cell carcinoma and human papillomavirus serological markers","volume":"104","author":"Sitas","year":"2012","journal-title":"J Natl Cancer Inst"},{"key":"key20200713185945_b28-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1038\/nature20805","article-title":"Integrated genomic characterization of oesophageal carcinoma","volume":"541","author":"Cancer Genome Atlas Research Network; Analysis Working Group; Asan University; BC Cancer Agency; Brigham and Women's Hospital; Broad Institute; Brown University; Case Western Reserve University; Dana-Farber Cancer Institute; Duke University","year":"2017","journal-title":"Nature"},{"key":"key20200713185945_b29-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"e88755","DOI":"10.1172\/jci.insight.88755","article-title":"Subtyping sub-Saharan esophageal squamous cell carcinoma by comprehensive molecular analysis","volume":"1","author":"Liu","year":"2016","journal-title":"JCI Insight"},{"key":"key20200713185945_b30-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"e5318","DOI":"10.1097\/MD.0000000000005318","article-title":"Human papillomavirus-related esophageal cancer survival: A systematic review and meta-analysis","volume":"95","author":"Guo","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"key20200713185945_b31-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1046\/j.1365-2133.1998.02222.x","article-title":"The prevalence of common skin conditions in Australian school students: 1. Common, plane and plantar viral warts","volume":"138","author":"Kilkenny","year":"1998","journal-title":"Br J Dermatol"},{"key":"key20200713185945_b32-ijo-55-03-0570","first-page":"59","article-title":"Host defenses against human papillomaviruses: Lessons from epidermodysplasia verruciformis","volume":"321","author":"Orth","year":"2008","journal-title":"Curr Top Microbiol Immunol"},{"key":"key20200713185945_b33-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"E229","DOI":"10.3390\/v9080229","article-title":"Targeting persistent human papillomavirus infection","volume":"9","author":"Shanmugasundaram","year":"2017","journal-title":"Viruses"},{"key":"key20200713185945_b34-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1038\/nm1598","article-title":"Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan","volume":"13","author":"Roberts","year":"2007","journal-title":"Nat Med"},{"key":"key20200713185945_b35-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1042\/CS20050369","article-title":"Molecular biology of human papillomavirus infection and cervical cancer","volume":"110","author":"Doorbar","year":"2006","journal-title":"Clin Sci (Lond)"},{"issue":"1 Suppl","key":"key20200713185945_b36-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"S12","DOI":"10.1016\/j.ygyno.2010.04.004","article-title":"Current understanding of the mechanism of HPV infection","volume":"118","author":"Schiller","year":"2010","journal-title":"Gynecol Oncol"},{"key":"key20200713185945_b37-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1128\/JVI.75.3.1565-1570.2001","article-title":"Human papillomavirus infection requires cell surface heparan sulfate","volume":"75","author":"Giroglou","year":"2001","journal-title":"J Virol"},{"key":"key20200713185945_b38-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"12961","DOI":"10.1128\/JVI.77.24.12961-12967.2003","article-title":"Further evidence that papillomavirus capsids exist in two distinct conformations","volume":"77","author":"Selinka","year":"2003","journal-title":"J Virol"},{"key":"key20200713185945_b39-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"4638","DOI":"10.1128\/JVI.00143-08","article-title":"Mechanisms of human papillomavirus type 16 neutralization by l2 cross-neutralizing and l1 type-specific antibodies","volume":"82","author":"Day","year":"2008","journal-title":"J Virol"},{"key":"key20200713185945_b40-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"20458","DOI":"10.1073\/pnas.0908502106","article-title":"The initial steps leading to papillomavirus infection occur on the basement membrane prior to cell surface binding","volume":"106","author":"Kines","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"key":"key20200713185945_b41-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"11426","DOI":"10.1128\/JVI.01721-13","article-title":"Multiple heparan sulfate binding site engagements are required for the infectious entry of human papillomavirus type 16","volume":"87","author":"Richards","year":"2013","journal-title":"J Virol"},{"key":"key20200713185945_b42-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1073\/pnas.0508815103","article-title":"Cleavage of the papillomavirus minor capsid protein, L2, at a furin consensus site is necessary for infection","volume":"103","author":"Richards","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"key20200713185945_b43-ijo-55-03-0570","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1128\/JVI.71.3.2449-2456.1997","article-title":"Identification of the alpha6 integrin as a candidate receptor for papillomaviruses","volume":"71","author":"Evander","year":"1997","journal-title":"J Virol"},{"key":"key20200713185945_b44-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.virol.2010.04.007","article-title":"Usage of heparan sulfate, integrins, and FAK in HPV16 infection","volume":"403","author":"Abban","year":"2010","journal-title":"Virology"},{"key":"key20200713185945_b45-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.virol.2012.08.032","article-title":"Use of an in vivo animal model for assessing the role of integrin a(6)\u03b2(4) and syndecan-1 in early steps in papillomavirus infection","volume":"433","author":"Huang","year":"2012","journal-title":"Virology"},{"key":"key20200713185945_b46-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.virol.2013.10.034","article-title":"HPV16 infection of HaCaTs is dependent on \u03b24 integrin, and a6 integrin processing","volume":"449","author":"Aksoy","year":"2014","journal-title":"Virology"},{"key":"key20200713185945_b47-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"893","DOI":"10.3390\/v6020893","article-title":"The tetraspanin CD151 in papillomavirus infection","volume":"6","author":"Scheffer","year":"2014","journal-title":"Viruses"},{"key":"key20200713185945_b48-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"e3313","DOI":"10.1371\/journal.pone.0003313","article-title":"Clathrin- and caveolin-independent entry of human papillomavirus type 16-involvement of tetraspanin-enriched microdomains (TEMs)","volume":"3","author":"Spoden","year":"2008","journal-title":"PLoS One"},{"key":"key20200713185945_b49-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"3435","DOI":"10.1128\/JVI.02906-12","article-title":"Tetraspanin CD151 mediates papillomavirus type 16 endocytosis","volume":"87","author":"Scheffer","year":"2013","journal-title":"J Virol"},{"key":"key20200713185945_b50-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"e1002519","DOI":"10.1371\/journal.ppat.1002519","article-title":"Essential roles for soluble virion-associated heparan sulfonated proteoglycans and growth factors in human papillomavirus infections","volume":"8","author":"Surviladze","year":"2012","journal-title":"PLoS Pathog"},{"key":"key20200713185945_b51-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"7038","DOI":"10.1128\/JVI.00234-15","article-title":"Kallikrein-8p roteolytically processes human papillomaviruses in the extracellular space to facilitate entry into host cells","volume":"89","author":"Cerqueira","year":"2015","journal-title":"J Virol"},{"key":"key20200713185945_b52-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.mrrev.2016.09.004","article-title":"HPV entry into cells","volume":"772","author":"Aksoy","year":"2017","journal-title":"Mutat Res Rev Mutat Res"},{"key":"key20200713185945_b53-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"e1000318","DOI":"10.1371\/journal.ppat.1000318","article-title":"Establishment of human papillomavirus infection requires cell cycle progression","volume":"5","author":"Pyeon","year":"2009","journal-title":"PLoS Pathog"},{"key":"key20200713185945_b54-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1016\/j.molcel.2006.11.005","article-title":"ChlR1 is required for loading papillomavirus E2 onto mitotic chromosomes and viral genome maintenance","volume":"24","author":"Parish","year":"2006","journal-title":"Mol Cell"},{"key":"key20200713185945_b55-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/S0065-3527(08)00404-1","article-title":"Replication and partitioning of papillomavirus genomes","volume":"72","author":"McBride","year":"2008","journal-title":"Adv Virus Res"},{"key":"key20200713185945_b56-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.virol.2009.07.029","article-title":"The stability of the human papillomavirus E6 oncoprotein is E6AP dependent","volume":"393","author":"Tomai\u0107","year":"2009","journal-title":"Virology"},{"key":"key20200713185945_b57-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"3276","DOI":"10.1128\/JVI.06450-11","article-title":"The E1 protein of human papillomavirus type 16 is dispensable for maintenance replication of the viral genome","volume":"86","author":"Egawa","year":"2012","journal-title":"J Virol"},{"issue":"Suppl 5","key":"key20200713185945_b58-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"F55","DOI":"10.1016\/j.vaccine.2012.06.083","article-title":"The biology and life-cycle of human papillomavi-ruses","volume":"30","author":"Doorbar","year":"2012","journal-title":"Vaccine"},{"key":"key20200713185945_b59-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"2832","DOI":"10.1128\/JVI.77.5.2832-2842.2003","article-title":"Quantitative role of the human papillomavirus type 16 E5 gene during the productive stage of the viral life cycle","volume":"77","author":"Genther","year":"2003","journal-title":"J Virol"},{"key":"key20200713185945_b60-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"2819","DOI":"10.1128\/JVI.77.5.2819-2831.2003","article-title":"Human papilloma-virus type 31 E5 protein supports cell cycle progression and activates late viral functions upon epithelial differentiation","volume":"77","author":"Fehrmann","year":"2003","journal-title":"J Virol"},{"key":"key20200713185945_b61-ijo-55-03-0570","first-page":"27","article-title":"Human papillomavirus type 16 E5 gene stimulates the transforming activity of the epidermal growth factor receptor","volume":"7","author":"Pim","year":"1992","journal-title":"Oncogene"},{"key":"key20200713185945_b62-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1128\/JVI.78.2.821-833.2004","article-title":"Functional analysis of the human papillomavirus type 16 E1=E4 protein provides a mechanism for in vivo and in vitro keratin filament reorganization","volume":"78","author":"Wang","year":"2004","journal-title":"J Virol"},{"key":"key20200713185945_b63-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"8196","DOI":"10.1128\/JVI.00509-08","article-title":"Structural analysis reveals an amyloid form of the human papillomavirus type 16 E1-E4 protein and provides a molecular basis for its accumulation","volume":"82","author":"McIntosh","year":"2008","journal-title":"J Virol"},{"key":"key20200713185945_b64-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.virol.2005.09.048","article-title":"The human papillomavirus type 11 E1-E4 protein is a transglutaminase 3 substrate and induces abnormalities of the cornified cell envelope","volume":"345","author":"Brown","year":"2006","journal-title":"Virology"},{"key":"key20200713185945_b65-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1002\/rmv.707","article-title":"Codon usage roles in human papilloma-virus","volume":"21","author":"Zhao","year":"2011","journal-title":"Rev Med Virol"},{"key":"key20200713185945_b66-ijo-55-03-0570","doi-asserted-by":"crossref","first-page":"4972","DOI":"10.1128\/JVI.73.6.4972-4982.1999","article-title":"Papillomavirus capsid protein expression level depends on the match between codon usage and tRNA availability","volume":"73","author":"Zhou","year":"1999","journal-title":"J Virol"},{"key":"key20200713185945_b67-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"5727","DOI":"10.1038\/sj.onc.1202960","article-title":"The human papilloma virus (HPV)-18 E6 oncoprotein physically associates with Tyk2 and impairs Jak-STAT activation by interferon-alpha","volume":"18","author":"Li","year":"1999","journal-title":"Oncogene"},{"key":"key20200713185945_b68-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.1101\/gad.12.13.2061","article-title":"Human papillomavirus 16 E6 oncoprotein binds to interferon regulatory factor-3 and inhibits its transcriptional activity","volume":"12","author":"Ronco","year":"1998","journal-title":"Genes Dev"},{"key":"key20200713185945_b69-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/S0304-3835(01)00871-0","article-title":"Abrogation of IRF-1 response by high-risk HPV E7 protein in vivo","volume":"179","author":"Um","year":"2002","journal-title":"Cancer Lett"},{"key":"key20200713185945_b70-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1006\/viro.2000.0584","article-title":"The human papilloma-virus E7 protein is able to inhibit the antiviral and anti-growth functions of interferon-alpha","volume":"277","year":"2000","journal-title":"Virology"},{"key":"key20200713185945_b71-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"5420","DOI":"10.4049\/jimmunol.167.9.5420","article-title":"Antigen processing defects in cervical carcinomas limit the presentation of a CTL epitope from human papillomavirus 16 E6","volume":"167","author":"Evans","year":"2001","journal-title":"J Immunol"},{"key":"key20200713185945_b72-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"8378","DOI":"10.1128\/JVI.77.15.8378-8385.2003","article-title":"Depletion of Langerhans cells in human papillomavirus type 16-infected skin is associated with E6-mediated down regulation of E-cadherin","volume":"77","author":"Matthews","year":"2003","journal-title":"J Virol"},{"key":"key20200713185945_b73-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"2236","DOI":"10.1007\/s10637-012-9803-0","article-title":"Screening of drugs to counteract human papillomavirus 16 E6 repression of E-cadherin expression","volume":"30","author":"D'Costa","year":"2012","journal-title":"Invest New Drugs"},{"key":"key20200713185945_b74-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"7172","DOI":"10.4049\/jimmunol.174.11.7172","article-title":"Human papillomavirus can escape immune recognition through Langerhans cell phosphoinositide 3-kinase activation","volume":"174","author":"Fausch","year":"2005","journal-title":"J Immunol"},{"key":"key20200713185945_b75-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"6151","DOI":"10.4049\/jimmunol.0902145","article-title":"A major role for the minor capsid protein of human papillomavirus type 16 in immune escape","volume":"183","author":"Fahey","year":"2009","journal-title":"J Immunol"},{"key":"key20200713185945_b76-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1046\/j.1365-2249.1999.00826.x","article-title":"The antigen-presenting environment in normal and human papillomavirus (HPV)-related premalignant cervical epithelium","volume":"116","author":"Mota","year":"1999","journal-title":"Clin Exp Immunol"},{"key":"key20200713185945_b77-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"5449","DOI":"10.1158\/0008-5472.CAN-04-0831","article-title":"Human papillomavirus type 16-positive cervical cancer is associated with impaired CD4+ T-cell immunity against early antigens E2 and E6","volume":"64","author":"de Jong","year":"2004","journal-title":"Cancer Res"},{"key":"key20200713185945_b78-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1159\/000334089","article-title":"Altered HLA class I and HLA-G expression is associated with IL-10 expression in patients with cervical cancer","volume":"79","author":"Rodriguez","year":"2012","journal-title":"Pathobiology"},{"key":"key20200713185945_b79-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1093\/intimm\/11.8.1351","article-title":"HLA-G-mediated inhibition of antigen-specific cytotoxic T lymphocytes","volume":"11","author":"Le Gal","year":"1999","journal-title":"Int Immunol"},{"key":"key20200713185945_b80-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"2355","DOI":"10.1016\/S0041-1345(01)02020-6","article-title":"A soluble HLA-G protein that inhibits natural killer cell-mediated cytotoxicity","volume":"33","author":"Marchal-Bras-Goncalves","year":"2001","journal-title":"Transplant Proc"},{"key":"key20200713185945_b81-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1002\/eji.200736918","article-title":"Soluble HLA-G molecules impair natural killer\/dendritic cell crosstalk via inhibition of dendritic cells","volume":"38","author":"Gros","year":"2008","journal-title":"Eur J Immunol"},{"key":"key20200713185945_b82-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1159\/000076642","article-title":"The HPV-16 E5 protein inhibits TRAIL- and FasL-mediated apoptosis in human keratinocyte raft cultures","volume":"47","author":"Kabsch","year":"2004","journal-title":"Intervirology"},{"key":"key20200713185945_b83-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/1476-4598-10-140","article-title":"Papillomavirus E5: The smallest oncopro-tein with many functions","volume":"10","author":"Venuti","year":"2011","journal-title":"Mol Cancer"},{"key":"key20200713185945_b84-ijo-55-03-0570","first-page":"6","article-title":"Modulation of apoptosis by early human papillomavirus proteins in cervical cancer","volume":"1805","author":"Lagunas-Mart\u00ednez","year":"2010","journal-title":"Biochim Biophys Acta"},{"key":"key20200713185945_b85-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"8058","DOI":"10.1073\/pnas.95.14.8058","article-title":"Basal and human papillomavirus E6 oncoprotein-induced degradation of Myc proteins by the ubiquitin pathway","volume":"95","author":"Gross-Mesilaty","year":"1998","journal-title":"Proc Natl Acad Sci USA"},{"key":"key20200713185945_b86-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"25729","DOI":"10.1074\/jbc.M401172200","article-title":"The human papillomavirus 16 E6 protein binds to Fas-associated death domain and protects cells from Fas-triggered apoptosis","volume":"279","author":"Filippova","year":"2004","journal-title":"J Biol Chem"},{"key":"key20200713185945_b87-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1038\/sj.cdd.4401886","article-title":"Accelerated degradation of FADD and procaspase 8 in cells expressing human papilloma virus 16 E6 impairs TRAIL-mediated apoptosis","volume":"13","author":"Garnett","year":"2006","journal-title":"Cell Death Differ"},{"key":"key20200713185945_b88-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"2321","DOI":"10.1007\/s00705-006-0821-0","article-title":"Modulation of apoptosis by human papillomavirus (HPV) oncoproteins","volume":"151","author":"Garnett","year":"2006","journal-title":"Arch Virol"},{"key":"key20200713185945_b89-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1128\/AAC.43.5.1198","article-title":"Selective inhibition of human papillomavirus-induced cell proliferation by (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine","volume":"43","author":"Johnson","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"key20200713185945_b90-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"10470","DOI":"10.1021\/acs.jmedchem.6b00659","article-title":"Synthesis and antiviral evaluation of octadecyloxyethyl Benzyl 9-[(2-Phosphonomethoxy)ethyl]guanine (ODE-Bn-PMEG), a potent inhibitor of transient HPV DNA amplification","volume":"59","author":"Beadle","year":"2016","journal-title":"J Med Chem"},{"key":"key20200713185945_b91-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.ygyno.2009.06.042","article-title":"Topical treatment of CIN 2+ by cidofovir: Results of a phase II, double-blind, prospective, placebo-controlled study","volume":"115","author":"Van Pachterbeke","year":"2009","journal-title":"Gynecol Oncol"},{"key":"key20200713185945_b92-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1016\/j.ygyno.2005.07.127","article-title":"Clinical responses to Cidofovir applied topically to women with high grade vulval intraepithe-lial neoplasia","volume":"99","author":"Tristram","year":"2005","journal-title":"Gynecol Oncol"},{"key":"key20200713185945_b93-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1097\/QAD.0b013e32835a9b16","article-title":"Safety and efficacy of topical cidofovir to treat high-grade perianal and vulvar intraepithelial neoplasia in HIV-positive men and women","volume":"27","author":"Stier","year":"2013","journal-title":"AIDS"},{"key":"key20200713185945_b94-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.ejmech.2014.03.051","article-title":"PMPA and PMEA prodrugs for the treatment of HIV infections and human papillomavirus (HPV) associated neoplasia and cancer","volume":"78","author":"Pertusati","year":"2014","journal-title":"Eur J Med Chem"},{"key":"key20200713185945_b95-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"2777","DOI":"10.1128\/AAC.00103-09","article-title":"GS-9191 is a novel topical prodrug of the nucleotide analog 9-(2-phosphonylmethoxyethyl)guanine with antiproliferative activity and possible utility in the treatment of human papilloma-virus lesions","volume":"53","author":"Wolfgang","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"key20200713185945_b96-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"2539","DOI":"10.1016\/S0960-894X(03)00510-9","article-title":"Discovery of the first series of inhibitors of human papilloma-virus type 11: Inhibition of the assembly of the E1-E2-Origin DNA complex","volume":"13","author":"Yoakim","year":"2003","journal-title":"Bioorg Med Chem Lett"},{"key":"key20200713185945_b97-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"26765","DOI":"10.1074\/jbc.M303608200","article-title":"Inhibition of human papillomavirus DNA replication by small molecule antagonists of the E1-E2 protein interaction","volume":"278","author":"White","year":"2003","journal-title":"J Biol Chem"},{"key":"key20200713185945_b98-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"6976","DOI":"10.1074\/jbc.M311376200","article-title":"Crystal structure of the E2 transactivation domain of human papillomavirus type 11 bound to a protein interaction inhibitor","volume":"279","author":"Wang","year":"2004","journal-title":"J Biol Chem"},{"key":"key20200713185945_b99-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1093\/nar\/gkg206","article-title":"Inhibition of human papilloma virus E2 DNA binding protein by covalently linked polyamides","volume":"31","author":"Schaal","year":"2003","journal-title":"Nucleic Acids Res"},{"key":"key20200713185945_b100-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.antiviral.2011.05.014","article-title":"HPV episome levels are potently decreased by pyrrole-imidazole polyamides","volume":"91","author":"Edwards","year":"2011","journal-title":"Antiviral Res"},{"key":"key20200713185945_b101-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.biochi.2016.04.022","article-title":"Interactions of two large antiviral polyamides with the long control region of HPV16","volume":"127","author":"Vasilieva","year":"2016","journal-title":"Biochimie"},{"key":"key20200713185945_b102-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1023\/A:1015336817836","article-title":"Papillomavirus E1 proteins: Form, function, and features","volume":"24","author":"Wilson","year":"2002","journal-title":"Virus Genes"},{"key":"key20200713185945_b103-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1038\/nrm1226","article-title":"Initiation of DNA replication: Lessons from viral initiator proteins","volume":"4","author":"Stenlund","year":"2003","journal-title":"Nat Rev Mol Cell Biol"},{"key":"key20200713185945_b104-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1021\/jm034206x","article-title":"Discovery of small-molecule inhibitors of the ATPase activity of human papillomavirus E1 helicase","volume":"47","author":"Faucher","year":"2004","journal-title":"J Med Chem"},{"key":"key20200713185945_b105-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"4834","DOI":"10.1128\/AAC.49.12.4834-4842.2005","article-title":"Biphenylsulfonacetic acid inhibitors of the human papillomavirus type 6 E1 helicase inhibit ATP hydrolysis by an allosteric mechanism involving tyrosine 486","volume":"49","author":"White","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"key20200713185945_b106-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1021\/bi0019592","article-title":"Solution structure determination and mutational analysis of the papillomavirus E6 interacting peptide of E6AP","volume":"40","author":"Be","year":"2001","journal-title":"Biochemistry"},{"key":"key20200713185945_b107-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.antiviral.2006.03.014","article-title":"Identification of inhibitors to papillomavirus type 16 E6 protein based on three-dimensional structures of interacting proteins","volume":"72","author":"Baleja","year":"2006","journal-title":"Antiviral Res"},{"key":"key20200713185945_b108-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"3533","DOI":"10.1128\/JVI.78.7.3533-3541.2004","article-title":"The binding of histone deacetylases and the integrity of zinc finger-like motifs of the E7 protein are essential for the life cycle of human papillomavirus type 31","volume":"78","author":"Longworth","year":"2004","journal-title":"J Virol"},{"key":"key20200713185945_b109-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"2449","DOI":"10.1093\/emboj\/18.9.2449","article-title":"The E7 oncoprotein associates with Mi2 and histone deacetylase activity to promote cell growth","volume":"18","author":"Brehm","year":"1999","journal-title":"Embo J"},{"key":"key20200713185945_b110-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1021\/jm0303655","article-title":"Zn2+-chelating motif-tethered short-chain fatty acids as a novel class of histone deacetylase inhibitors","volume":"47","author":"Lu","year":"2004","journal-title":"J Med Chem"},{"key":"key20200713185945_b111-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.bmcl.2004.10.074","article-title":"Identification of a potent non-hydroxamate histone deacetylase inhibitor by mechanism-based drug design","volume":"15","author":"Suzuki","year":"2005","journal-title":"Bioorg Med Chem Lett"},{"key":"key20200713185945_b112-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1021\/jm049207j","article-title":"Novel inhibitors of human histone deacetylases: Design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxamates","volume":"48","author":"Suzuki","year":"2005","journal-title":"J Med Chem"},{"key":"key20200713185945_b113-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"3001","DOI":"10.1021\/jm980565u","article-title":"Synthesis and histone deacety-lase inhibitory activity of new benzamide derivatives","volume":"42","author":"Suzuki","year":"1999","journal-title":"J Med Chem"},{"key":"key20200713185945_b114-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1006\/excr.1998.4027","article-title":"FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor","volume":"241","author":"Nakajima","year":"1998","journal-title":"Exp Cell Res"},{"key":"key20200713185945_b115-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1006\/viro.2002.1667","article-title":"Growth arrest of HPV-positive cells after histone deacetylase inhibition is independent of E6\/E7 oncogene expression","volume":"304","author":"Finzer","year":"2002","journal-title":"Virology"},{"key":"key20200713185945_b116-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"4768","DOI":"10.1038\/sj.onc.1204652","article-title":"Inhibitors of histone deacetylase arrest cell cycle and induce apoptosis in cervical carcinoma cells circumventing human papillomavirus oncogene expression","volume":"20","author":"Finzer","year":"2001","journal-title":"Oncogene"},{"key":"key20200713185945_b117-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/1475-2867-6-2","article-title":"Antineoplastic effects of the DNA methylation inhibitor hydralazine and the histone deacetylase inhibitor valproic acid in cancer cell lines","volume":"6","author":"Chavez-Blanco","year":"2006","journal-title":"Cancer Cell Int"},{"key":"key20200713185945_b118-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1002\/rmv.488","article-title":"Human papillomaviruses: Basic mechanisms of pathogenesis and oncogenicity","volume":"16","author":"Hebner","year":"2006","journal-title":"Rev Med Virol"},{"key":"key20200713185945_b119-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"6167","DOI":"10.1074\/jbc.275.9.6167","article-title":"HeLa cells are phenotypically limiting in cyclin E\/CDK2 for efficient human papillomavirus DNA replication","volume":"275","author":"Lin","year":"2000","journal-title":"J Biol Chem"},{"key":"key20200713185945_b120-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1073\/pnas.96.2.382","article-title":"Interaction between cyclin-dependent kinases and human papillomavirus replication-initiation protein E1 is required for efficient viral replication","volume":"96","author":"Ma","year":"1999","journal-title":"Proc Natl Acad Sci USA"},{"key":"key20200713185945_b121-ijo-55-03-0570","doi-asserted-by":"crossref","first-page":"7255","DOI":"10.1128\/JVI.72.9.7255-7262.1998","article-title":"Functional interaction between the bovine papillomavirus virus type 1 replicative helicase E1 and cyclin E-Cdk2","volume":"72","author":"Cueille","year":"1998","journal-title":"J Virol"},{"key":"key20200713185945_b122-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"6241","DOI":"10.1038\/sj.onc.1205709","article-title":"Human papillomaviruses and centrosome duplication errors: Modeling the origins of genomic instability","volume":"21","author":"Duensing","year":"2002","journal-title":"Oncogene"},{"key":"key20200713185945_b123-ijo-55-03-0570","first-page":"383","article-title":"Centrosome abnormalities and genomic instability induced by human papillomavirus oncoproteins","volume":"5","author":"Duensing","year":"2003","journal-title":"Prog Cell Cycle Res"},{"key":"key20200713185945_b124-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"7712","DOI":"10.1128\/JVI.75.16.7712-7716.2001","article-title":"Centrosome abnormalities and genomic instability by episomal expression of human papillomavirus type 16 in raft cultures of human keratinocytes","volume":"75","author":"Duensing","year":"2001","journal-title":"J Virol"},{"key":"key20200713185945_b125-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1128\/JVI.01170-06","article-title":"Nucleocytoplasmic shuttling of bovine papillomavirus E1 helicase downregulates viral DNA replication in S phase","volume":"81","author":"Hsu","year":"2007","journal-title":"J Virol"},{"key":"key20200713185945_b126-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"13954","DOI":"10.1128\/JVI.78.24.13954-13965.2004","article-title":"Cyclin\/CDK regulates the nucleocy-toplasmic localization of the human papillomavirus E1 DNA helicase","volume":"78","author":"Deng","year":"2004","journal-title":"J Virol"},{"key":"key20200713185945_b127-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1093\/jac\/dkf227","article-title":"Cyclin-dependent kinases as cellular targets for antiviral drugs","volume":"50","author":"Schang","year":"2002","journal-title":"J Antimicrob Chemother"},{"key":"key20200713185945_b128-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/S0304-3835(01)00827-8","article-title":"Roscovitine inhibits ongoing DNA synthesis in human cervical cancer","volume":"180","author":"Vitali","year":"2002","journal-title":"Cancer Lett"},{"key":"key20200713185945_b129-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"8206","DOI":"10.1038\/sj.onc.1208012","article-title":"Cyclin-dependent kinase inhibitor indirubin-3\u2032-oxime selectively inhibits human papillomavirus type 16 E7-induced numerical centrosome anomalies","volume":"23","author":"Duensing","year":"2004","journal-title":"Oncogene"},{"key":"key20200713185945_b130-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"2447","DOI":"10.1016\/j.bmcl.2015.03.066","article-title":"Discovery of novel indirubin-3\u2032-monoxime derivatives as potent inhibitors against CDK2 and CDK9","volume":"25","author":"Yan","year":"2015","journal-title":"Bioorg Med Chem Lett"},{"key":"key20200713185945_b131-ijo-55-03-0570","doi-asserted-by":"crossref","first-page":"5577","DOI":"10.1128\/JVI.64.11.5577-5584.1990","article-title":"The E6\/E7 promoter of human papillomavirus type 16 is activated in the absence of E2 proteins by a sequence-aberrant Sp1 distal element","volume":"64","author":"Gloss","year":"1990","journal-title":"J Virol"},{"key":"key20200713185945_b132-ijo-55-03-0570","doi-asserted-by":"crossref","first-page":"6476","DOI":"10.1128\/JVI.67.11.6476-6486.1993","article-title":"Transcriptional control of human papillomavirus (HPV) oncogene expression: Composition of the HPV type 18 upstream regulatory region","volume":"67","author":"Butz","year":"1993","journal-title":"J Virol"},{"key":"key20200713185945_b133-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/S0166-3542(00)00089-9","article-title":"Inhibition of human papillomavirus type 16 gene expression by nordihydroguaiaretic acid plant lignan derivatives","volume":"47","author":"Craigo","year":"2000","journal-title":"Antiviral Res"},{"key":"key20200713185945_b134-ijo-55-03-0570","first-page":"5499","article-title":"Tetra-O-methyl nordihydroguaiaretic acid induces G2 arrest in mammalian cells and exhibits tumoricidal activity in vivo","volume":"61","author":"Heller","year":"2001","journal-title":"Cancer Res"},{"key":"key20200713185945_b135-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1093\/aje\/kwt077","article-title":"Clinical progression of high-grade cervical intraepithelial neoplasia: Estimating the time to preclinical cervical cancer from doubly censored national registry data","volume":"178","author":"Vink","year":"2013","journal-title":"Am J Epidemiol"},{"key":"key20200713185945_b136-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1038\/314111a0","article-title":"Structure and transcription of human papillomavirus sequences in cervical carcinoma cells","volume":"314","author":"Schwarz","year":"1985","journal-title":"Nature"},{"key":"key20200713185945_b137-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.cancergencyto.2004.08.021","article-title":"The role of viral integration in the development of cervical cancer","volume":"158","author":"Yu","year":"2005","journal-title":"Cancer Genet Cytogenet"},{"key":"key20200713185945_b138-ijo-55-03-0570","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1128\/JVI.69.5.2989-2997.1995","article-title":"Integration of human papillomavirus type 16 into the human genome correlates with a selective growth advantage of cells","volume":"69","author":"Jeon","year":"1995","journal-title":"J Virol"},{"key":"key20200713185945_b139-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1073\/pnas.92.5.1654","article-title":"Integration of human papillomavirus type 16 DNA into the human genome leads to increased stability of E6 and E7 mRNAs: Implications for cervical carcinogenesis","volume":"92","author":"Jeon","year":"1995","journal-title":"Proc Natl Acad Sci USA"},{"key":"key20200713185945_b140-ijo-55-03-0570","first-page":"2","article-title":"Listeria-based vaccines can overcome tolerance by expanding low avidity CD8+ T cells capable of eradicating a solid tumor in a transgenic mouse model of cancer","volume":"7","author":"Souders","year":"2007","journal-title":"Cancer Immun"},{"key":"key20200713185945_b141-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"5315","DOI":"10.1016\/j.vaccine.2008.07.036","article-title":"Listeria-based HPV-16 E7 vaccines limit autochthonous tumor growth in a transgenic mouse model for HPV-16 transformed tumors","volume":"26","author":"Sewell","year":"2008","journal-title":"Vaccine"},{"key":"key20200713185945_b142-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"2810","DOI":"10.1016\/j.vaccine.2010.02.005","article-title":"Oral immunization with a Lactobacillus casei vaccine expressing human papil-lomavirus (HPV) type 16 E7 is an effective strategy to induce mucosal cytotoxic lymphocytes against HPV16 E7","volume":"28","author":"Adachi","year":"2010","journal-title":"Vaccine"},{"key":"key20200713185945_b143-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1128\/AEM.68.2.917-922.2002","article-title":"Production of human papillomavirus type 16 E7 protein in Lactococcus lactis","volume":"68","author":"Bermudez-Humaran","year":"2002","journal-title":"Appl Environ Microbiol"},{"key":"key20200713185945_b144-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1099\/jmm.0.05472-0","article-title":"An inducible surface presentation system improves cellular immunity against human papillomavirus type 16 E7 antigen in mice after nasal administration with recombinant lactococci","volume":"53","author":"Bermudez-Humaran","year":"2004","journal-title":"J Med Microbiol"},{"key":"key20200713185945_b145-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1080\/10611860400024219","article-title":"Cell-surface display of E7 antigen from human papillomavirus type-16 in Lactococcus lactis and in Lactobacillus plantarum using a new cell-wall anchor from lactobacilli","volume":"13","author":"Cortes-Perez","year":"2005","journal-title":"J Drug Target"},{"key":"key20200713185945_b146-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1007\/s002620050302","article-title":"Induction of an antibody response in mice against human papillomavirus (HPV) type 16 after immunization with HPV recombinant Salmonella strains","volume":"43","author":"Krul","year":"1996","journal-title":"Cancer Immunol Immunother"},{"key":"key20200713185945_b147-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"6233","DOI":"10.1016\/j.vaccine.2014.09.020","article-title":"Oral vaccination against HPV E7 for treatment of cervical intraepithelial neoplasia grade 3 (CIN3) elicits E7-specific mucosal immunity in the cervix of CIN3 patients","volume":"32","author":"Kawana","year":"2014","journal-title":"Vaccine"},{"key":"key20200713185945_b148-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1016\/j.micinf.2007.05.005","article-title":"Listeriolysin O: A phagosome-specific lysin","volume":"9","author":"Schnupf","year":"2007","journal-title":"Microbes Infect"},{"key":"key20200713185945_b149-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1158\/2326-6066.CIR-13-0197","article-title":"Episomal expression of truncated listeriolysin O in LmddA-LLO-E7 vaccine enhances antitumor efficacy by preferentially inducing expansions of CD4+FoxP3- and CD8+ T cells","volume":"2","author":"Chen","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"key20200713185945_b150-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1016\/S0264-410X(02)00554-6","article-title":"Enhancing the immunogenicity of bioengineered Listeria monocytogenes by passaging through live animal hosts","volume":"21","author":"Peters","year":"2003","journal-title":"Vaccine"},{"key":"key20200713185945_b151-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"3975","DOI":"10.1016\/j.vaccine.2009.04.041","article-title":"The first clinical use of a live-attenuated Listeria monocytogenes vaccine: A Phase I safety study of Lm-LLO-E7 in patients with advanced carcinoma of the cervix","volume":"27","author":"Maciag","year":"2009","journal-title":"Vaccine"},{"key":"key20200713185945_b152-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1016\/S0140-6736(96)90674-1","article-title":"A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer","volume":"347","author":"Borysiewicz","year":"1996","journal-title":"Lancet"},{"key":"key20200713185945_b153-ijo-55-03-0570","first-page":"3676","article-title":"Safety and immunogenicity of TA-HPV, a recombinant vaccinia virus expressing modified human papillomavirus (HPV)-16 and HPV-18 E6 and E7 genes, in women with progressive cervical cancer","volume":"8","author":"Kaufmann","year":"2002","journal-title":"Clin Cancer Res"},{"key":"key20200713185945_b154-ijo-55-03-0570","first-page":"5205","article-title":"Vaccinia-expressed human papillomavirus 16 and 18 e6 and e7 as a therapeutic vaccination for vulval and vaginal intraepithelial neoplasia","volume":"9","author":"Baldwin","year":"2003","journal-title":"Clin Cancer Res"},{"key":"key20200713185945_b155-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"169.e1","DOI":"10.1016\/j.ajog.2010.09.020","article-title":"Regression of high-grade cervical intraepithelial neoplasia with TG4001 targeted immunotherapy","volume":"204","author":"Brun","year":"2011","journal-title":"Am J Obstet Gynecol"},{"key":"key20200713185945_b156-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1089\/hum.2014.024","article-title":"Regression of human papillomavirus intraepithelial lesions is induced by MVA E2 therapeutic vaccine","volume":"25","author":"Rosales","year":"2014","journal-title":"Hum Gene Ther"},{"key":"key20200713185945_b157-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1007\/s00262-006-0247-2","article-title":"Vaccination with an adenoviral vector expressing calreticulin-human papilloma-virus 16 E7 fusion protein eradicates E7 expressing established tumors in mice","volume":"56","author":"Gomez-Gutierrez","year":"2007","journal-title":"Cancer Immunol Immunother"},{"key":"key20200713185945_b158-ijo-55-03-0570","doi-asserted-by":"crossref","first-page":"3904","DOI":"10.4049\/jimmunol.152.8.3904","article-title":"Role of HLA-A motifs in identification of potential CTL epitopes in human papillomavirus type 16 E6 and E7 proteins","volume":"152","author":"Kast","year":"1994","journal-title":"J Immunol"},{"key":"key20200713185945_b159-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1056\/NEJMoa0810097","article-title":"Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia","volume":"361","author":"Kenter","year":"2009","journal-title":"N Engl J Med"},{"key":"key20200713185945_b160-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1007\/s00262-012-1292-7","article-title":"A placebo-controlled randomized HPV16 synthetic long-peptide vaccination study in women with high-grade cervical squamous intraepithelial lesions","volume":"61","author":"de Vos van Steenwijk","year":"2012","journal-title":"Cancer Immunol Immunother"},{"key":"key20200713185945_b161-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/1479-5876-11-88","article-title":"HPV16 synthetic long peptide (HPV16-SLP) vaccination therapy of patients with advanced or recurrent HPV16-induced gynecological carcinoma, a phase II trial","volume":"11","author":"van Poelgeest","year":"2013","journal-title":"J Transl Med"},{"key":"key20200713185945_b162-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s00262-013-1499-2","article-title":"The long-term immune response after HPV16 peptide vaccination in women with low-grade pre-malignant disorders of the uterine cervix: A placebo-controlled phase II study","volume":"63","author":"de Vos van Steenwijk","year":"2014","journal-title":"Cancer Immunol Immunother"},{"key":"key20200713185945_b163-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"334ra52","DOI":"10.1126\/scitranslmed.aad8307","article-title":"Vaccination during myeloid cell depletion by cancer chemotherapy fosters robust T cell responses","volume":"8","author":"Welters","year":"2016","journal-title":"Sci Transl Med"},{"key":"key20200713185945_b164-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1007\/s00262-016-1821-x","article-title":"Human papillomavirus type 16 viral load is decreased following a therapeutic vaccination","volume":"65","author":"Coleman","year":"2016","journal-title":"Cancer Immunol Immunother"},{"key":"key20200713185945_b165-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"109","DOI":"10.2165\/11532810-000000000-00000","article-title":"Immunotherapy for cervical cancer: Research status and clinical potential","volume":"24","author":"Su","year":"2010","journal-title":"BioDrugs"},{"key":"key20200713185945_b166-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"3456","DOI":"10.1016\/S0264-410X(02)00350-X","article-title":"Enhancement of human papillomavirus (HPV) type 16 E6 and E7-specific T-cell immunity in healthy volunteers through vaccination with TA-CIN, an HPV16 L2E7E6 fusion protein vaccine","volume":"20","author":"de Jong","year":"2002","journal-title":"Vaccine"},{"key":"key20200713185945_b167-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1038\/sj.bjc.6605611","article-title":"Phase II trial of imiquimod and HPV therapeutic vaccination in patients with vulval intraepithelial neoplasia","volume":"102","author":"Daayana","year":"2010","journal-title":"Br J Cancer"},{"key":"key20200713185945_b168-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"3238","DOI":"10.1158\/1078-0432.CCR-16-0085","article-title":"GTL001, A therapeutic vaccine for women infected with human papillomavirus 16 or 18 and normal cervical cytology: Results of a phase I clinical trial","volume":"22","author":"Van Damme","year":"2016","journal-title":"Clin Cancer Res"},{"key":"key20200713185945_b169-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1016\/j.vaccine.2010.11.083","article-title":"A novel fusion protein-based vaccine comprising a cell penetrating and immunostimulatory peptide linked to human papillomavirus (HPV) type 16 E7 antigen generates potent immunologic and anti-tumor responses in mice","volume":"29","author":"Granadillo","year":"2011","journal-title":"Vaccine"},{"key":"key20200713185945_b170-ijo-55-03-0570","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1128\/CDLI.7.4.669-675.2000","article-title":"A Limulus antilipopolysaccharide factor-derived peptide exhibits a new immunological activity with potential applicability in infectious diseases","volume":"7","author":"Vallespi","year":"2000","journal-title":"Clin Diagn Lab Immunol"},{"key":"key20200713185945_b171-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"24199","DOI":"10.1038\/srep24199","article-title":"Carboxyl-terminal fusion of E7 into Flagellin shifts TLR5 activation to NLRC4\/NAIP5 activation and induces TLR5-independent anti-tumor immunity","volume":"6","author":"Lin","year":"2016","journal-title":"Sci Rep"},{"key":"key20200713185945_b172-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"e51","DOI":"10.3802\/jgo.2016.27.e51","article-title":"Immunotherapy for human papillomavirus-associated disease and cervical cancer: Review of clinical and translational research","volume":"27","author":"Lee","year":"2016","journal-title":"J Gynecol Oncol"},{"key":"key20200713185945_b173-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1080\/14760584.2016.1176533","article-title":"Targeting immune response with therapeutic vaccines in premalignant lesions and cervical cancer: Hope or reality from clinical studies","volume":"15","author":"Vici","year":"2016","journal-title":"Expert Rev Vaccines"},{"key":"key20200713185945_b174-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s12929-016-0293-9","article-title":"Perspectives for therapeutic HPV vaccine development","volume":"23","author":"Yang","year":"2016","journal-title":"J Biomed Sci"},{"key":"key20200713185945_b175-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"4036","DOI":"10.1016\/S0264-410X(03)00275-5","article-title":"Comparison of the CD8+ T cell responses and antitumor effects generated by DNA vaccine administered through gene gun, biojector, and syringe","volume":"21","author":"Trimble","year":"2003","journal-title":"Vaccine"},{"key":"key20200713185945_b176-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"5450","DOI":"10.1016\/j.vaccine.2009.07.005","article-title":"Administration of HPV DNA vaccine via electroporation elicits the strongest CD8+ T cell immune responses compared to intramuscular injection and intradermal gene gun delivery","volume":"27","author":"Best","year":"2009","journal-title":"Vaccine"},{"key":"key20200713185945_b177-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/1423-0127-16-36","article-title":"Femtosecond laser treatment enhances DNA transfection efficiency in vivo","volume":"16","author":"Tsen","year":"2009","journal-title":"J Biomed Sci"},{"key":"key20200713185945_b178-ijo-55-03-0570","first-page":"1028","article-title":"Encapsulated plasmid DNA treatment for human papilloma-virus 16-associated anal dysplasia: A Phase I study of ZYC101","volume":"8","author":"Klencke","year":"2002","journal-title":"Clin Cancer Res"},{"key":"key20200713185945_b179-ijo-55-03-0570","first-page":"1080","article-title":"Enhancement of DNA vaccine potency by linkage of antigen gene to a gene encoding the extracellular domain of Fms-like tyrosine kinase 3-ligand","volume":"61","author":"Hung","year":"2001","journal-title":"Cancer Res"},{"key":"key20200713185945_b180-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/S1046-2023(03)00136-1","article-title":"Augmentation of DNA vaccine potency through secretory heat shock protein-mediated antigen targeting","volume":"31","author":"Hauser","year":"2003","journal-title":"Methods"},{"key":"key20200713185945_b181-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.vaccine.2004.07.010","article-title":"Plasmid encoding papillomavirus Type 16 (HPV16) DNA constructed with codon optimization improved the immunogenicity against HPV infection","volume":"23","author":"Cheung","year":"2004","journal-title":"Vaccine"},{"key":"key20200713185945_b182-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1006\/viro.2002.1584","article-title":"Codon modified human papillomavirus type 16 E7 DNA vaccine enhances cytotoxic T-lymphocyte induction and anti-tumour activity","volume":"301","author":"Liu","year":"2002","journal-title":"Virology"},{"key":"key20200713185945_b183-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/s11373-006-9086-6","article-title":"A DNA vaccine encoding a codon-optimized human papillomavirus type 16 E6 gene enhances CTL response and anti-tumor activity","volume":"13","author":"Lin","year":"2006","journal-title":"J Biomed Sci"},{"key":"key20200713185945_b184-ijo-55-03-0570","first-page":"93","article-title":"Enhancement of T cell-mediated and humoral immunity of beta-glucuronidase-based DNA vaccines against HPV16 E7 oncoprotein","volume":"33","author":"Smahel","year":"2008","journal-title":"Int J Oncol"},{"key":"key20200713185945_b185-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1089\/hum.2007.122","article-title":"Antitumor activity of DNA vaccines based on the human papillomavirus-16 E7 protein genetically fused to a plant virus coat protein","volume":"19","author":"Massa","year":"2008","journal-title":"Hum Gene Ther"},{"key":"key20200713185945_b186-ijo-55-03-0570","first-page":"1035","article-title":"Enhancement of DNA vaccine potency by linkage of antigen gene to an HSP70 gene","volume":"60","author":"Chen","year":"2000","journal-title":"Cancer Res"},{"key":"key20200713185945_b187-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1172\/JCI200112346","article-title":"Tumor-specific immunity and antiangiogenesis generated by a DNA vaccine encoding calreticulin linked to a tumor antigen","volume":"108","author":"Cheng","year":"2001","journal-title":"J Clin Invest"},{"key":"key20200713185945_b188-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"3362","DOI":"10.1016\/j.vaccine.2008.03.082","article-title":"Enhanced immunogenicity of HPV16E7 accompanied by Gp96 as an adjuvant in two vaccination strategies","volume":"26","author":"Bolhassani","year":"2008","journal-title":"Vaccine"},{"key":"key20200713185945_b189-ijo-55-03-0570","first-page":"3698","article-title":"Cancer immunotherapy using a DNA vaccine encoding the translocation domain of a bacterial toxin linked to a tumor antigen","volume":"61","author":"Hung","year":"2001","journal-title":"Cancer Res"},{"key":"key20200713185945_b190-ijo-55-03-0570","first-page":"2393","article-title":"Enhancing major histocompatibility complex class I antigen presentation by targeting antigen to centrosomes","volume":"63","author":"Hung","year":"2003","journal-title":"Cancer Res"},{"key":"key20200713185945_b191-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1038\/sj.gt.3302519","article-title":"Cancer immunotherapy using a DNA vaccine encoding a single-chain trimer of MHC class I linked to an HPV-16 E6 immunodominant CTL epitope","volume":"12","author":"Huang","year":"2005","journal-title":"Gene Ther"},{"key":"key20200713185945_b192-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"2970","DOI":"10.4049\/jimmunol.171.6.2970","article-title":"Enhancing DNA vaccine potency by combining a strategy to prolong dendritic cell life with intracellular targeting strategies","volume":"171","author":"Kim","year":"2003","journal-title":"J Immunol"},{"key":"key20200713185945_b193-ijo-55-03-0570","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1158\/0008-5472.309.65.1","article-title":"Modification of professional antigen-presenting cells with small interfering RNA in vivo to enhance cancer vaccine potency","volume":"65","author":"Kim","year":"2005","journal-title":"Cancer Res"},{"key":"key20200713185945_b194-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1089\/hum.2007.059","article-title":"RNA interference-mediated in vivo silencing of fas ligand as a strategy for the enhancement of DNA vaccine potency","volume":"19","author":"Huang","year":"2008","journal-title":"Hum Gene Ther"},{"key":"key20200713185945_b195-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1016\/S0140-6736(15)00239-1","article-title":"Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2\/3: A randomised, double-blind, placebo-controlled phase 2b trial","volume":"386","author":"Trimble","year":"2015","journal-title":"Lancet"},{"key":"key20200713185945_b196-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"5317","DOI":"10.1038\/ncomms6317","article-title":"Clearance of persistent HPV infection and cervical lesion by therapeutic DNA vaccine in CIN3 patients","volume":"5","author":"Kim","year":"2014","journal-title":"Nat Commun"},{"key":"key20200713185945_b197-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"221ra13","DOI":"10.1126\/scitranslmed.3007323","article-title":"Intramuscular therapeutic vaccination targeting HPV16 induces T cell responses that localize in mucosal lesions","volume":"6","author":"Maldonado","year":"2014","journal-title":"Sci Transl Med"},{"key":"key20200713185945_b198-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.ygyno.2015.11.026","article-title":"A pilot study of pNGVL4a-CRT\/E7(detox) for the treatment of patients with HPV16+ cervical intraepithelial neoplasia 2\/3 (CIN2\/3)","volume":"140","author":"Alvarez","year":"2016","journal-title":"Gynecol Oncol"},{"key":"key20200713185945_b199-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1038\/sj.gt.3302164","article-title":"Enhancement of suicidal DNA vaccine potency by delaying suicidal DNA-induced cell death","volume":"11","author":"Kim","year":"2004","journal-title":"Gene Ther"},{"key":"key20200713185945_b200-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"4394","DOI":"10.1128\/JVI.74.9.4394-4403.2000","article-title":"Stable high-level expression of heterologous genes in vitro and in vivo by noncy-topathic DNA-based Kunjin virus replicon vectors","volume":"74","author":"Varnavski","year":"2000","journal-title":"J Virol"},{"key":"key20200713185945_b201-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.virol.2003.10.032","article-title":"Recombinant Kunjin virus replicon vaccines induce protective T-cell immunity against human papillomavirus 16 E7-expressing tumour","volume":"319","author":"Herd","year":"2004","journal-title":"Virology"},{"key":"key20200713185945_b202-ijo-55-03-0570","first-page":"5456","article-title":"Adenoviral vectors targeted to CD40 enhance the efficacy of dendritic cell-based vaccination against human papillomavirus 16-induced tumor cells in a murine model","volume":"60","author":"Tillman","year":"2000","journal-title":"Cancer Res"},{"key":"key20200713185945_b203-ijo-55-03-0570","first-page":"1581","article-title":"Adjuvant effect of dendritic cells transduced with recombinant vaccinia virus expressing HPV16-E7 is inhibited by co-expression of IL12","volume":"24","author":"Mackova","year":"2004","journal-title":"Int J Oncol"},{"key":"key20200713185945_b204-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1038\/sj.gt.3301160","article-title":"Intramuscular administration of E7-transfected dendritic cells generates the most potent E7-specific anti-tumor immunity","volume":"7","author":"Wang","year":"2000","journal-title":"Gene Ther"},{"key":"key20200713185945_b205-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/1479-5876-6-21","article-title":"Whole tumor antigen vaccination using dendritic cells: Comparison of RNA electroporation and pulsing with UV-irradiated tumor cells","volume":"6","author":"Benencia","year":"2008","journal-title":"J Transl Med"},{"key":"key20200713185945_b206-ijo-55-03-0570","first-page":"1184","article-title":"Induction of specific CD8+ T-lymphocyte responses using a human papillomavirus-16 E6\/E7 fusion protein and autologous dendritic cells","volume":"59","author":"Murakami","year":"1999","journal-title":"Cancer Res"},{"key":"key20200713185945_b207-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1089\/hum.2005.16.584","article-title":"Vaccination with dendritic cells transfected with BAK and BAX siRNA enhances antigen-specific immune responses by prolonging dendritic cell life","volume":"16","author":"Peng","year":"2005","journal-title":"Hum Gene Ther"},{"key":"key20200713185945_b208-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.imlet.2008.12.006","article-title":"Enhancement of dendritic cell-based vaccine potency by anti-apoptotic siRNAs targeting key pro-apoptotic proteins in cytotoxic CD8(+) T cell-mediated cell death","volume":"122","author":"Kim","year":"2009","journal-title":"Immunol Lett"},{"key":"key20200713185945_b209-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1016\/S0264-410X(02)00599-6","article-title":"Dendritic cell (DC) based therapy for cervical cancer: Use of DC pulsed with tumour lysate and matured with a novel synthetic clinically non-toxic double stranded RNA analogue poly (I):poly (C(12)U) (Ampligen R)","volume":"21","author":"Adams","year":"2003","journal-title":"Vaccine"},{"key":"key20200713185945_b210-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1111\/cei.12620","article-title":"The siRNA cocktail targeting interleukin 10 receptor and transforming growth factor-\u03b2 receptor on dendritic cells potentiates tumour antigen-specific CD8(+) T cell immunity","volume":"181","author":"Ahn","year":"2015","journal-title":"Clin Exp Immunol"},{"key":"key20200713185945_b211-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.ygyno.2005.09.040","article-title":"HPV16\/18 E7-pulsed dendritic cell vaccination in cervical cancer patients with recurrent disease refractory to standard treatment modalities","volume":"100","author":"Santin","year":"2006","journal-title":"Gynecol Oncol"},{"key":"key20200713185945_b212-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"1968","DOI":"10.1128\/JVI.02343-07","article-title":"Human papillomavirus type 16 and 18 E7-pulsed dendritic cell vaccination of stage IB or IIA cervical cancer patients: A phase I escalating-dose trial","volume":"82","author":"Santin","year":"2008","journal-title":"J Virol"},{"key":"key20200713185945_b213-ijo-55-03-0570","first-page":"593","article-title":"Interleukin 2 gene therapy of residual disease in mice carrying tumours induced by HPV 16","volume":"14","author":"Bubenik","year":"1999","journal-title":"Int J Oncol"},{"key":"key20200713185945_b214-ijo-55-03-0570","first-page":"161","article-title":"Treatment of minimal residual disease after surgery or chemotherapy in mice carrying HPV16-associated tumours: Cytokine and gene therapy with IL-2 and GM-CSF","volume":"24","author":"Mikyskova","year":"2004","journal-title":"Int J Oncol"},{"key":"key20200713185945_b215-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1002\/(SICI)1097-0215(19990505)81:3<428::AID-IJC17>3.0.CO;2-#","article-title":"Interleukin-12-secreting human papillomavirus type 16-transformed cells provide a potent cancer vaccine that generates E7-directed immunity","volume":"81","author":"Hallez","year":"1999","journal-title":"Int J Cancer"},{"key":"key20200713185945_b216-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1002\/(SICI)1097-0215(20000601)86:5<725::AID-IJC19>3.0.CO;2-K","article-title":"Antigen-specific cancer immunotherapy using a GM-CSF secreting allogeneic tumor cell-based vaccine","volume":"86","author":"Chang","year":"2000","journal-title":"Int J Cancer"},{"key":"key20200713185945_b217-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1007\/978-0-387-72005-0_37","article-title":"Tumor cell vaccines","volume":"601","author":"Thompson","year":"2007","journal-title":"Adv Exp Med Biol"},{"key":"key20200713185945_b218-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1200\/JCO.2014.58.9093","article-title":"Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells","volume":"33","author":"Stevanovi\u0107","year":"2015","journal-title":"J Clin Oncol"},{"key":"key20200713185945_b219-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"4431","DOI":"10.1158\/1078-0432.CCR-14-3341","article-title":"Targeting of HPV-16+ epithelial cancer cells by TCR gene engineered T cells directed against E6","volume":"21","author":"Draper","year":"2015","journal-title":"Clin Cancer Res"},{"key":"key20200713185945_b220-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1016\/S0190-9622(99)70261-6","article-title":"Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream","volume":"41","author":"Beutner","year":"1999","journal-title":"J Am Acad Dermatol"},{"key":"key20200713185945_b221-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1097\/00128360-200310000-00011","article-title":"Treatment of vaginal intraepithelial neoplasia (primarily low grade) with imiquimod 5% cream","volume":"7","author":"Buck","year":"2003","journal-title":"J Low Genit Tract Dis"},{"key":"key20200713185945_b222-ijo-55-03-0570","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.ygyno.2010.12.340","article-title":"Treatment of vulvar intraepithelial neoplasia with topical imiquimod: Seven years median follow-up of a randomized clinical trial","volume":"121","author":"Terlou","year":"2011","journal-title":"Gynecol Oncol"},{"key":"key20200713185945_b223-ijo-55-03-0570","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1097\/QAD.0b013e32833d466c","article-title":"A double-blind, randomized controlled trial of the use of imiquimod cream for the treatment of anal canal high-grade anal intraepithelial neoplasia in HIV-positive MSM on HAART, with long-term follow-up data including the use of open-label imiquimod","volume":"24","author":"Fox","year":"2010","journal-title":"Aids"}],"container-title":["International Journal of Oncology"],"original-title":[],"deposited":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T13:01:56Z","timestamp":1695042116000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/ijo.2019.4847"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,23]]},"references-count":223,"URL":"https:\/\/doi.org\/10.3892\/ijo.2019.4847","relation":{},"ISSN":["1019-6439","1791-2423"],"issn-type":[{"value":"1019-6439","type":"print"},{"value":"1791-2423","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,23]]}}}